Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Accumulated Expenses (2022 - 2025)

CervoMed's Accumulated Expenses history spans 9 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 339.32% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, up 339.32%, while the annual FY2024 figure was $2.4 million, 666.14% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $3.3 million at CervoMed, up from $2.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.3 million in Q3 2025 and bottomed at $206675.0 in Q4 2022.
  • The 4-year median for Accumulated Expenses is $482162.0 (2024), against an average of $924505.7.
  • The largest annual shift saw Accumulated Expenses tumbled 59.86% in 2023 before it soared 666.14% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $206675.0 in 2022, then soared by 49.54% to $309062.0 in 2023, then skyrocketed by 666.14% to $2.4 million in 2024, then surged by 37.26% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Accumulated Expenses are $3.3 million (Q3 2025), $2.8 million (Q2 2025), and $385866.0 (Q1 2025).